Homocysteine, smoking and vascular disease

European Heart Journal

Volumn 23, Issue 20, 2002, Pages 1559-1560

  Wilcken, D E L ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID ANTAGONIST; HOMOCYSTEINE; METHIONINE; VITAMIN B GROUP;

AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CORONARY ARTERY DISEASE; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; EDITORIAL; HOMOCYSTINURIA; HUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; VASCULAR DISEASE; VITAMIN SUPPLEMENTATION;

HOMOCYSTEINE; HUMANS; SMOKING; VASCULAR DISEASES;

EID: 0036797272     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.2002.3271     Document Type: Editorial

References (18)

1. Carson N, Cusworth D, Dent C et al. Homocystinuria: A new inborn error of metabolism associated with mental deficiency. Archives of Diseases in Childhood 1963; 38: 425-36.
2. Mudd S, Finkelstein J, Irreverre F et al. Homocystinuria: An enzymatic defect. Science 1964; 143: 1443-5.
3. McCully KS. Vascular pathology of homocysteinemia: Implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969; 56: 111-28.
4. Mudd SH, Skovby F, Levy HL et al. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet 1985; 37: 1-31.
5. Wilcken DE, Wilcken B. The natural history of vascular disease in homocystinuria and the effects of treatment. J Inherit Metab Dis 1997; 20: 295-300.
6. Yap S, Boers GH, Wilcken B et al. Vascular outcome in patients with homocystinuria due to cystathionine beta-synthase deficiency treated chronically: A multicenter observational study. Arterioscler Thromb Vasc Biol 2001; 21: 2080-5.
7. Wilcken DE, Wilcken B. The pathogenesis of coronary artery diseasel A possible role for methionine metabolism. J Clin Invest 1976; 57: 1079-82.
8. Wang XL, Tam C, McCredie RM et al. Determinants of severity of coronary artery disease in Australian men and women. Circulation 1994; 89: 1974-81.
9. Refsum H, Ueland PM, Nygard O et al. Homocysteine and cardiovascular disease. Annu Rev Med 1998; 49: 31-62.
10. Seshadri S, Beiser A, Selhub J et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002; 346: 476-83.
11. Nygard O, Vollset SE, Refsum H et al. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA 1995; 274: 1526-33.
12. O'Callaghan P, Meleady R, Fitzgerald T et al. Smoking and plasma homocysteine. Eur Heart J 2002; 23: 1580-6.
13. Doshi SN, McDowell IF, Moat SJ et al. Folate improves endothelial function in coronary artery disease: An effect mediated by reduction of intracellular superoxide? Arterioscler Thromb Vasc Biol 2001; 21: 1196-202.
14. Verhaar MC, Stroes E, Rabelink TJ. Folates and cardiovascular disease. Arterioscler Thromb Vasc Biol 2002; 22: 6-13.
15. Usui M, Matsuoka H, Miyazaki H et al. Endothelial dysfunction by acute hyperhomocyst(e)inaemia: Restoration by folic acid. Clin Sci (Lond) 1999; 96: 235-9.
16. Yamamoto M, Hara H, Adachi T. Effects of homocysteine on the binding of extracellular-superoxide dismutase to the endothelial cell surface. FEBS Lett 2000; 486: 159-62.
17. Morrow JD, Frei B, Longmire AW et al. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med 1995; 332: 1198-203.
18. Clarke R, Collins R. Can dietary supplements with folic acid or vitamin B6 reduce cardiovascular risk? Design of clinical trials to test the homocysteine hypothesis of vascular disease. J Cardiovasc Risk 1998; 5: 249-55.